Kallikrein-Kinin system in neovascularization

Arteriosclerosis, Thrombosis, and Vascular Biology

Volumn 29, Issue 5, 2009, Pages 617-619

  Bader, Michael ^a  

^a MAX DELBRÜCK CENTER FOR MOLECULAR MEDICINE   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN; BRADYKININ; BRADYKININ B1 RECEPTOR; BRADYKININ B2 RECEPTOR; BRADYKININ B2 RECEPTOR ANTAGONIST; CALCINEURIN; CALCIUM ION; DIPEPTIDYL CARBOXYPEPTIDASE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENDOTHELIAL NITRIC OXIDE SYNTHASE; FIBROBLAST GROWTH FACTOR 1; FIBROBLAST GROWTH FACTOR 2; G PROTEIN COUPLED RECEPTOR; GELATINASE B; KALLIKREIN; KALLIKREIN INHIBITOR; KININOGEN; METALLOPROTEINASE; NITRIC OXIDE; PEPTIDE HORMONE; PROTEIN KINASE B; VASCULOTROPIN; VASCULOTROPIN ANTIBODY; VASCULOTROPIN RECEPTOR 2;

ANGIOGENESIS; CARBOXY TERMINAL SEQUENCE; CARDIOLOGIST; CELL MIGRATION; CELL PROLIFERATION; DIABETIC RETINOPATHY; EDITORIAL; ENDOTHELIUM CELL; ENZYME ACTIVATION; ENZYME ACTIVITY; GENE OVEREXPRESSION; HEART INFARCTION; HINDLIMB; HUMAN; KALLIKREIN KININ SYSTEM; LIMB ISCHEMIA; NEOVASCULARIZATION (PATHOLOGY); NONHUMAN; ONCOLOGY; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; RETINA MACULA AGE RELATED DEGENERATION; RHEUMATOID ARTHRITIS; SIGNAL TRANSDUCTION; STEM CELL; ANIMAL; ISCHEMIA; MOUSE; MOUSE MUTANT; NOTE; PATHOPHYSIOLOGY; PHYSIOLOGY; RAT;

ANIMALS; ENDOTHELIAL CELLS; HUMANS; ISCHEMIA; KALLIKREIN-KININ SYSTEM; MICE; MICE, KNOCKOUT; NEOVASCULARIZATION, PATHOLOGIC; NEOVASCULARIZATION, PHYSIOLOGIC; RATS;

EID: 65549091963     PISSN: 10795642     EISSN: None     Source Type: Journal    
DOI: 10.1161/ATVBAHA.109.184549     Document Type: Editorial

References (25)

1. Stone OA, Richer C, Emanueli C, van W, V, Quax PH, Katare R, Kraenkel N, Campagnolo P, Barcelos LS, Siragusa M, Sala-Newby GB, Baldessari D, Mione M, Vincent MP, Benest AV, Al Haj ZA, Gonzalez J, Bates DO, Alhenc-Gelas F, Madeddu P. Critical role of tissue kallikrein in vessel formation and maturation: implications for therapeutic revascu-larization. Arterioscler Thromb Vasc Biol. 2009;29:657- 664.
2. Leeb-Lundberg LM, Marceau F, Muller-Esterl W, Pettibone DJ, Zuraw BL. International union of pharmacology. XLV. Classification of the kinin receptor family: from molecular mechanisms to pathophysiological consequences. Pharmacol Rev. 2005;57:27-77.
3. 9-bradykinin inhibits the angiogenic effect of bradykinin and interleukin-1 in rats. Br J Pharmacol. 1993;109: 14-17.
4. Clozel JP, Kuhn H, Hefti F. Effects of chronic ACE inhibition on cardiac hypertrophy and coronary vascular reserve in spontaneously hypertensive rats with developed hypertension. J Hypertens. 1989;7:267-275.
5. Takeshita S, Tomiyama H, Yokoyama N, Kawamura Y, Furukawa T, Ishigai Y, Shibano T, Isshiki T, Sato T. Angiotensin-converting enzyme inhibition improves defective angiogenesis in the ischemic limb of spontaneously hypertensive rats. Cardiovasc Res. 2001;52:314-320.
6. Silvestre JS, Bergaya S, Tamarat R, Duriez M, Boulanger CM, Levy BI. Proangiogenic effect of angiotensin-converting enzyme inhibition is mediated by the bradykinin B(2) receptor pathway. Circ Res. 2001;89: 678-683.
7. Ikeda Y, Hayashi I, Kamoshita E, Yamazaki A, Endo H, Ishihara K, Yamashina S, Tsutsumi Y, Matsubara H, Majima M. Host stromal bra-dykinin B2 receptor signaling facilitates tumor-associated angiogenesis and tumor growth. Cancer Res. 2004;64:5178-5185.
8. Colman RW, Jameson BA, Lin Y, Johnson D, Mousa SA. Domain 5 of high molecular weight kininogen (kininostatin) down-regulates endothe-lial cell proliferation and migration and inhibits angiogenesis. Blood. 2000;95:543-550.
9. Song JS, Sainz IM, Cosenza SC, Isordia-Salas I, Bior A, Bradford HN, Guo YL, Pixley RA, Reddy EP, Colman RW. Inhibition of tumor angio-genesis in vivo by a monoclonal antibody targeted to domain 5 of high molecular weight kininogen. Blood. 2004;104:2065-2072.
10. Emanueli C, Salis MB, Stacca T, Pintus G, Kirchmayr R, Isner JM, Pinna A, Gaspa L, Regoli D, Cayla C, Pesquero JB, Bader M, Madeddu P. Targeting kinin B1 receptor for therapeutic angiogenesis. Circulation. 2002;105:360-366.
11. Sanchez dM, Neysari S, Jakob S, Petrimpol M, Butz N, Banfi A, Zaugg CE, Humar R, Battegay EJ. B2-kinin receptor plays a key role in B1-, angiotensin converting enzyme inhibitor-, and vascular endothelial growth factor-stimulated in vitro angiogenesis in the hypoxic mouse heart. Cardiovasc Res. 2008;80:106-113.
12. Emanueli C, Minasi A, Zacheo A, Chao J, Chao L, Salis MB, Straino S, Tozzi MG, Smith R, Gaspa L, Bianchini G, Stillo F, Capogrossi MC, Madeddu P. Local delivery of human tissue kallikrein gene accelerates spontaneous angiogenesis in mouse model of hindlimb ischemia. Circulation. 2001;103:125-132.
13. Xia CF, Yin H, Yao YY, Borlongan CV, Chao L, Chao J. Kallikrein protects against ischemic stroke by inhibiting apoptosis and inflammation and promoting angiogenesis and neurogenesis. Hum Gene Ther. 2006; 17:206-219.
14. Smith RS Jr, Gao L, Chao L, Chao J. Tissue kallikrein and kinin infusion promotes neovascularization in limb ischemia. Biol Chem. 2008;389: 725-730.
15. Li P, Kondo T, Numaguchi Y, Kobayashi K, Aoki M, Inoue N, Okumura K, Murohara T. Role of bradykinin, nitric oxide, and angiotensin II type 2 receptor in imidapril-induced angiogenesis. Hypertension. 2008;51: 252-258.
16. Thuringer D, Maulon L, Frelin C. Rapid transactivation of the vascular endothelial growth factor receptor KDR/Flk-1 by the bradykinin B2 receptor contributes to endothelial nitric-oxide synthase activation in cardiac capillary endothelial cells. J Biol Chem. 2002;277:2028-2032.
17. Yao YY, Yin H, Shen B, Smith RS Jr, Liu Y, Gao L, Chao L, Chao J. Tissue kallikrein promotes neovascularization and improves cardiac function by the Akt-glycogen synthase kinase-3beta pathway. Cardiovasc Res. 2008;80:354-364.
18. Harris MB, Ju H, Venema VJ, Liang H, Zou R, Michell BJ, Chen ZP, Kemp BE, Venema RC. Reciprocal phosphorylation and regulation of endothelial nitric-oxide synthase in response to bradykinin stimulation. J Biol Chem. 2001;276:16587-16591.
19. Parenti A, Morbidelli L, Ledda F, Granger HJ, Ziche M. The bradyki-nin/B1 receptor promotes angiogenesis by up-regulation of endogenous FGF-2 in endothelium via the nitric oxide synthase pathway. FASEB J. 2001;15:1487-1489.
20. Krankel N, Katare RG, Siragusa M, Barcelos LS, Campagnolo P, Mangialardi G, Fortunato O, Spinetti G, Tran N, Zacharowski K, Woja-kowski W, Mroz I, Herman A, Manning Fox JE, MacDonald PE, Schanstra JP, Bascands JL, Ascione R, Angelini G, Emanueli C, Madeddu P. Role of kinin B2 receptor signaling in the recruitment of circulating progenitor cells with neovascularization potential. Circ Res. 2008;103:1335-1343.
21. Maestri R, Milia AF, Salis MB, Graiani G, Lagrasta C, Monica M, Corradi D, Emanueli C, Madeddu P. Cardiac hypertrophy and micro-vascular deficit in kinin B2 receptor knockout mice. Hypertension. 2003; 41:1151-1155.
22. Trabold F, Pons S, Hagege AA, Bloch-Faure M, Alhenc-Gelas F, Giudicelli JF, Richer-Giudicelli C, Meneton P. Cardiovascular pheno-types of kinin B2 receptor- and tissue kallikrein-deficient mice. Hypertension. 2002;40:90-95.
23. Tschesche H, Michaelis J, Kohnert U, Fedrowitz J, Oberhoff R. Tissue kallikrein effectively activates latent matrix degrading metalloenzymes. Adv Exp Med Biol. 1989;247A:545-548.
24. Stewart JM, Chan DC, Simkeviciene V, Bunn PA Jr, Helfrich B, York EJ, Taraseviciene-Stewart L, Bironaite D, Gera L. Bradykinin antagonists as new drugs for prostate cancer. Int Immunopharmacol. 2002;2:1781-1786.
25. Phipps JA, Clermont AC, Sinha S, Chilcote TJ, Bursell SE, Feener EP. Plasma kallikrein mediates angiotensin II type 1 receptor-stimulated retinal vascular permeability. Hypertension. 2009;53:175-181.